- Home
- PRGO vs ADRX Comparison
PRGO vs ADRX Comparison
Compare PRGO & ADRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRGO | ADRX |
|---|---|---|
| Founded | 1887 | 2019 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 1.9B |
| IPO Year | 2013 | 2026 |
Fundamental Metrics
Financial Performance| Metric | PRGO | ADRX |
|---|---|---|
| Price | $16.23 | $14.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $18.00 | ★ $34.25 |
| AVG Volume (30 Days) | ★ 2.2M | 396.7K |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | ★ 7.17% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $800,000.00 | N/A |
| Revenue This Year | N/A | $89.41 |
| Revenue Next Year | N/A | $510.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.23 | $12.50 |
| 52 Week High | $17.02 | $19.57 |
Technical Indicators
Market Signals| Indicator | PRGO | ADRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.47 | 39.02 |
| Support Level | $9.93 | $12.50 |
| Resistance Level | $16.79 | $18.94 |
| Average True Range (ATR) | 0.70 | 1.59 |
| MACD | -0.02 | -0.16 |
| Stochastic Oscillator | 60.79 | 30.24 |
Price Performance
Historical ComparisonAbout PRGO Perrigo Company plc
Perrigo is a pure-play consumer healthcare product manufacturer and distributor. In North America (two-thirds of total sales), the firm's product mix centers on private-label consumer health goods sold to major retailers such as Walmart, Amazon.com, Costco, and CVS. It plays in a number of over-the-counter categories including pain, skincare, women's health, and nutrition. Perrigo also competes in Europe, Australia, and parts of Asia, where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
About ADRX ADARx Pharmaceuticals Inc. Common Stock
Adarx Pharmaceuticals Inc is a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. Its pipeline includes three clinical-stage programs and two advanced preclinical programs. The three hepatic-targeted programs are agazisiran, onvuzosiran, and ADX-626, while the two extrahepatic-targeted programs are ADX-077 and ADX-199.